Entecavir, Tenofovir Comparable in Patients with Treatment-Naïve Chronic Hepatitis B

SAN FRANCISCO, CA—Third-year results of a “real-world” cohort study found the antivirals entecavir and tenofovir provided comparable efficacy for treatment-naïve patients with chronic hepatitis B and high genetic barriers against resistance, a study concluded at IDWeek 2013.

Although HBeAg seroconversion rates at year three were significantly higher with entecavir, the rates increased with time in both groups and were converging, reported Dr. Fehmi Tabak of the department of infectious diseases at the Cerrahpasa Medical Faculty, Istanbul, Turkey and colleagues.

Read more....